CL2020002993A1 - Terapias combinadas para la ateroesclerosis, incluyendo la enfermedad cardiovascular ateroesclerótica (divisional de solicitud no 1304-2019) - Google Patents

Terapias combinadas para la ateroesclerosis, incluyendo la enfermedad cardiovascular ateroesclerótica (divisional de solicitud no 1304-2019)

Info

Publication number
CL2020002993A1
CL2020002993A1 CL2020002993A CL2020002993A CL2020002993A1 CL 2020002993 A1 CL2020002993 A1 CL 2020002993A1 CL 2020002993 A CL2020002993 A CL 2020002993A CL 2020002993 A CL2020002993 A CL 2020002993A CL 2020002993 A1 CL2020002993 A1 CL 2020002993A1
Authority
CL
Chile
Prior art keywords
atherosclerosis
pcsk9
ldl
cardiovascular disease
divisional application
Prior art date
Application number
CL2020002993A
Other languages
English (en)
Inventor
Ransi Mudalinayake Somaratne
Robert Andrew Donald Scott
Scott Wasserman
Narimon Honarpour
Stephen Nicholls
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60484496&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2020002993(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CL2020002993A1 publication Critical patent/CL2020002993A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

En el presente documento se proporcionan combinaciones de terapias que posibilitan el tratamiento, incluyendo la regresión, de la ateroesclerosis y/o la mejora de los resultados cardiovasculares. Descrito de modo general, esto incluye un primer agente reductor del LDL-C distinto de PCSK9 (tal como una estatina u otra terapia reductora de LDL-C distinta de PCSK9), combinado con una segunda terapia con inhibidor de PCSK9 (tal como un anticuerpo contra PCSK9 o anti-ARN). Se ha determinado que la aplicación de ambas terapias, a niveles adecuadamente elevadas a fin de reducir el nivel de LDL-C del sujeto hasta niveles muy bajos, durante un periodo de tiempo adecuado, proporciona un beneficio añadido de protección adicional frente a la ateroesclerosis y mejora los resultados cardiovasculares de un sujeto.
CL2020002993A 2016-11-14 2020-11-18 Terapias combinadas para la ateroesclerosis, incluyendo la enfermedad cardiovascular ateroesclerótica (divisional de solicitud no 1304-2019) CL2020002993A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662421685P 2016-11-14 2016-11-14
US201762471874P 2017-03-15 2017-03-15
US201762515117P 2017-06-05 2017-06-05
US201762581244P 2017-11-03 2017-11-03
US201762584600P 2017-11-10 2017-11-10

Publications (1)

Publication Number Publication Date
CL2020002993A1 true CL2020002993A1 (es) 2021-05-14

Family

ID=60484496

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2019001304A CL2019001304A1 (es) 2016-11-14 2019-05-13 Terapias combinadas para la ateroesclerosis, incluyendo la enfermedad cardiovascular ateroesclerótica.
CL2020002993A CL2020002993A1 (es) 2016-11-14 2020-11-18 Terapias combinadas para la ateroesclerosis, incluyendo la enfermedad cardiovascular ateroesclerótica (divisional de solicitud no 1304-2019)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2019001304A CL2019001304A1 (es) 2016-11-14 2019-05-13 Terapias combinadas para la ateroesclerosis, incluyendo la enfermedad cardiovascular ateroesclerótica.

Country Status (17)

Country Link
US (1) US20200368350A1 (es)
EP (1) EP3538149A2 (es)
JP (2) JP2019533715A (es)
KR (1) KR20190085963A (es)
CN (1) CN110234350A (es)
AU (1) AU2017356219A1 (es)
BR (1) BR112019009726A2 (es)
CA (1) CA3043700A1 (es)
CL (2) CL2019001304A1 (es)
CO (1) CO2019004814A2 (es)
IL (1) IL266579A (es)
JO (1) JOP20190112A1 (es)
MA (1) MA46758A (es)
MX (1) MX2019005627A (es)
TN (1) TN2019000156A1 (es)
WO (1) WO2018089912A2 (es)
ZA (1) ZA201902975B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015289874A1 (en) * 2014-07-14 2017-02-02 Amgen Inc. Crystalline antibody formulations
JOP20190215A1 (ar) 2017-03-24 2019-09-19 Ionis Pharmaceuticals Inc مُعدّلات التعبير الوراثي عن pcsk9
AU2019315823A1 (en) * 2018-07-31 2021-04-01 Wen Tan New use of carbamate beta phenylethanolamine analogues for enhancing intracellular clearance of ldl cholesterol and for combining therapy with statins to enhance the efficacy and reduce adverse effects
CN114127770A (zh) * 2019-07-19 2022-03-01 电子湾有限公司 样本增量监视
CN112656792B (zh) * 2021-01-26 2022-07-05 首都医科大学宣武医院 洛美他派在制备用于治疗脑卒中引起的神经损伤药物中的用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3249052B1 (en) 2006-05-11 2019-04-10 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the pcsk9 gene
AR070315A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
AR070316A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US9493774B2 (en) * 2009-01-05 2016-11-15 Rxi Pharmaceuticals Corporation Inhibition of PCSK9 through RNAi
BRPI1010689A2 (pt) 2009-06-15 2016-03-15 Alnylam Pharmaceuticals Inc "dsrna formulado por lipídios direcionados para o gene pcsk9"
AR079336A1 (es) 2009-12-11 2012-01-18 Irm Llc Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
MA34818B1 (fr) 2010-12-22 2014-01-02 Genentech Inc Anticorps anti-pcsk9 et procédés d'utilisation
CN103562227B (zh) 2011-02-11 2016-12-21 诺瓦提斯公司 Pcsk9拮抗剂
JOP20200043A1 (ar) * 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
AR087715A1 (es) 2011-09-16 2014-04-09 Lilly Co Eli Anticuerpos anti pcsk9 y usos de los mismos
WO2015142668A1 (en) * 2014-03-17 2015-09-24 Sanofi Methods for reducing cardiovascular risk
EP3650852B1 (en) * 2015-01-09 2021-08-18 Global Genomics Group, LLC Blood based biomarkers for diagnosing atherosclerotic coronary artery disease

Also Published As

Publication number Publication date
MX2019005627A (es) 2019-10-14
WO2018089912A2 (en) 2018-05-17
MA46758A (fr) 2019-09-18
JOP20190112A1 (ar) 2019-05-14
KR20190085963A (ko) 2019-07-19
JP2023071715A (ja) 2023-05-23
JP2019533715A (ja) 2019-11-21
BR112019009726A2 (pt) 2019-08-13
TN2019000156A1 (en) 2020-10-05
CO2019004814A2 (es) 2019-07-31
CN110234350A (zh) 2019-09-13
WO2018089912A3 (en) 2018-06-21
CA3043700A1 (en) 2018-05-17
ZA201902975B (en) 2020-01-29
CL2019001304A1 (es) 2019-09-23
IL266579A (en) 2019-07-31
US20200368350A1 (en) 2020-11-26
EP3538149A2 (en) 2019-09-18
AU2017356219A1 (en) 2019-05-30

Similar Documents

Publication Publication Date Title
CL2020002993A1 (es) Terapias combinadas para la ateroesclerosis, incluyendo la enfermedad cardiovascular ateroesclerótica (divisional de solicitud no 1304-2019)
CL2017000080A1 (es) Métodos para tratar el cáncer con inhibidores de tigit y agentes contra el cáncer
CO2017011197A2 (es) Terapia de combinación fgfr/pd-1 para el tratamiento del cancer
GT201700167A (es) Terapias de combinación para el tratamiento de cánceres.
CR20150376A (es) Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos
CL2016002372A1 (es) Cenicriviroc para el tratamiento de la fibrosis.
AR102553A1 (es) Terapia de combinación con agonistas de unión ox40 e inhibidores de tigit
PE20211069A1 (es) Composicion que comprende 5'-metilselenoadenosina, selenoadenosil-l-homocisteina y gama glutamil-metilselenocisteina
CR20150216A (es) Composiciones y métodos para tratar proteinopatías
CL2020000384A1 (es) Métodos para tratar y/o prevenir la enfermedad de injerto contra huésped y/o hemorragia alveolar difusa y/o enfermedad veno-oclusiva asociada con trasplante de células madre hematopoyéticas.
CL2018001258A1 (es) Métodos para tratar las condiciones asociadas con la activación del complemento dependiente de masp-2
CL2019002218A1 (es) Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
CL2017001964A1 (es) Encapsulado de agentes activos de alta potencia.
CL2015002171A1 (es) Métodos de tratamiento de la dificiencia de hierro con pirofosfato férrico soluble.
CL2019002574A1 (es) Moduladores de la expresión de pcsk9.
CO2017012645A2 (es) Agente antihipertensivo que comprende s-1-propenilcisteína o una sal del mismo como ingrediente activo
PE20221421A1 (es) METODO PARA EL TRATAMIENTO DE CANCER UTILIZANDO CELULA ADYUVANTE ARTIFICIAL (aAVC)
SV2016005308A (es) Composiciã“n farmacã‰utica para el tratamiento de alopatã�as relacionadas con el dolor, usando como agente activo al ketorolaco trometamina y clorhidrato de tramadol
CL2021000892A1 (es) Avexitida para el tratamiento de la hipoglucemia hiperinsulinémica
AR103636A1 (es) Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol
PE20220250A1 (es) Uso de docetaxel en el tratamiento de cancer mediante control de niveles maximos en plasma
CL2019003288A1 (es) Una combinación farmacéutica para el tratamiento de un cáncer.
MX2020004731A (es) Terapias de combinacion de inhibidor ezh2.
CL2018002200A1 (es) Administración combinada de un agente de penetración y un compuesto de azufre que contiene compuesto para las plantas.
EA201991160A1 (ru) Средства комбинированной терапии атеросклероза, включая атеросклеротическое сердечно-сосудистое заболевание